Clinical Trial

A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy

Name: A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy — clinical trial record (NCT06756321)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Early Phase 1

View on ClinicalTrials.gov →

Record status

This record was last updated January 3, 2025 (before its estimated March 18, 2025 completion). Its status may not reflect the trial's current state.

Summary

This study is a single-center, open-label clinical trial of single-dose of CAR T-cells in subjects with relapsed/refractory hematologic malignancy.

Trial Details

NCT Number	NCT06756321
Lead Sponsor	Affiliated Hospital of Nantong University Collaborators: Shanghai First Song Biotechnology Co., LTD
Conditions	Relapsed/refractory Lymphoma, Relapsed/Refractory Leukemia
Enrollment	9 participants
Start Date	2023-09-18
Primary Completion	2025-03-18 (estimated)
Study Completion	2026-03-18 (estimated)
Updated on ClinicalTrials.gov	2025-01-03